Torii Pharmaceutical Co Ltd
TSE:4551
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its 3-Year Average (12), the stock would be worth ¥3 582.42 (43% downside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 21.2 | ¥6 330 |
0%
|
| 3-Year Average | 12 | ¥3 582.42 |
-43%
|
| 5-Year Average | 9.7 | ¥2 895.13 |
-54%
|
| Industry Average | 17.5 | ¥5 222.07 |
-18%
|
| Country Average | 13.6 | ¥4 076.34 |
-36%
|
Forward EV/EBIT
Today’s price vs future ebit
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| JP |
|
Torii Pharmaceutical Co Ltd
TSE:4551
|
178B JPY | 21.2 | 32.9 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
853.2B USD | 29.8 | 41.3 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
544.6B USD | 21.2 | 25.9 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 13.2 | 19.8 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
225.8B GBP | 22.8 | 29.2 | |
| CH |
|
Novartis AG
SIX:NOVN
|
226.8B CHF | 15.9 | 19.9 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
278.5B USD | 11.6 | 15.3 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 970 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 9.4 | 10.9 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
155.3B USD | 10.2 | 20 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
119.6B USD | 8.8 | 17 |
Market Distribution
| Min | 0.1 |
| 30th Percentile | 9.8 |
| Median | 13.6 |
| 70th Percentile | 18.1 |
| Max | 414 821 439 |
Other Multiples
Torii Pharmaceutical Co Ltd
Glance View
Torii Pharmaceutical Co., Ltd. engages in the manufacturing and marketing of pharmaceutical products. The company is headquartered in Chuo-Ku, Tokyo-To and currently employs 560 full-time employees. The company went IPO on 2013-10-01. The Company’s main product categories include oral pruritus improving agents, proteolytic enzyme inhibitors, hyperkalemia improving agents, topical adrenocortical hormones, allergen immunotherapy for cedar pollinosis, allergen immunotherapy for mite allergy, active viable bacterial preparations, uterine contraction inhibitors in premature birth and others. The Company’s main products include Remitch, Riona tablets, Keixalate, Yulinome tablets, Antebate, Locoid, Zefnate, Sida Torengi pollen sublingual solution, Miticure mite sublingual tablet, Biosley, Magcent and others.
